| Literature DB >> 32799908 |
Siqi Dai1, Xiaowen Huang1, Yuxiang Chen1, Menglei Wang1, Huanxin Zheng1, Kang Zeng2, Li Li3.
Abstract
BACKGROUND: Bilateral herpes zoster (BHZ) is an atypical presentation of herpes zoster (HZ), with few cases reported before. Ramsay Hunt syndrome (RHS) is an uncommon complication of VZV infection. Cases of BHZ with RHS in immunocompetent adults have been reported rarely. CASEEntities:
Keywords: Antiviral therapy; Bilateral herpes zoster (BHZ); Glucocorticoid; Ramsay hunt syndrome (RHS); Varicella-zoster virus (VZV)
Mesh:
Substances:
Year: 2020 PMID: 32799908 PMCID: PMC7429785 DOI: 10.1186/s12985-020-01392-0
Source DB: PubMed Journal: Virol J ISSN: 1743-422X Impact factor: 4.099
Fig. 1Diffused erythema and clustered vesicles affecting the left T4-T5 dermatome, shown in panel (a). Facial nerve and auditory nerve was involved in zoster of the right ear, shown in panel (b)
Fig. 2Some noteworthy information with regards to the clinical effect has been recorded within the observation of this patient during the period from Feb 18 to Apr 09 in 2019. From Feb 18 to Feb 25, the right facial palsy with lagophthalmus had initially improved with a slight change. By Mar 9, the patient could almost close his right eyelid. However, there was no significant change for flattened nasolabial old and droopy corners of the mouth on the right side within this period. By Apr 9, the right facial palsy had been resolved
Overview of reported cases of bilateral herpes zoster (BHZ)
| NO. | Age | Sex | Dermatomes | Symmetry | Underlying disease | Treatment | Reference (see supplementary materials for details) |
|---|---|---|---|---|---|---|---|
| 1 | 61 | M | R: T2–3 L: C5-T1 | Asymmetry | / | VCV oral 1 g/q8h 7 days | 1 |
| 2 | 24 | F | R: L1–2 L: maxillary dermatome | Asymmetry | / | ACV oral 800 mg × 5/d 10 days | 2 |
| 3 | 7 | M | R: C4 L: T3–4, L2 | Asymmetry | / | ACV oral 800 mg × 5/d 7 days | 3 |
| 4 | 16 | M | R: trigeminal nerve dermatome L: T4–7 | Asymmetry | / | ACV oral 500 mg × 3/d 7 days | 4 |
| 5 | 45 | M | R: T9 L: trigeminal nerve dermatome | Asymmetry | / | ACV IV 10 mg/kg × 3/d | 5 |
| 6 | 26 | M | R: T8 L: T9 | Asymmetry | / | ACV 800 mg × 5/d 7 days | 6 |
| 7 | 73 | F | R: L1–2 L: T9–10 | Asymmetry | / | Isoprinosine 1.000 mg × 4/d | 7 |
| 8 | 60 | M | R: trigeminal nerve dermatome, forearm L: back | Asymmetry | / | Prednisolone oral 40 mg/d topical ACV and steroids | 8 |
| 9 | 40 | F | R: neck and ear L: neck and shoulder | Asymmetry | / | Quinine, iron and sulphateof magnesia oral | 9 |
| 10 | 28 | M | R: T8–9 L: T12, L1–2 | Asymmetry | / | ACV oral 800 mg × 5/d 7 days | 10 |
| 11 | 14 | M | R: forehead L: L1 | Asymmetry | / | ACV IV 1500 mg/m2/dClindamycin IV | 11 |
| 12 | 21 | M | Trigeminal nerve dermatome | Symmetry | / | ? | 12 |
| 13 | 3 | M | Face, nose, chin and ear | Symmetry | / | Triple sulfa and penicillin | 12 |
| 14 | 41 | F | Neck | Symmetry | / | No treatment | 12 |
| 15 | 15 | M | T7–9 | Symmetry | / | ACV 800 mg × 5/d 7 days | 13 |
| 16 | 33 | F | Upper sacral areas, hips, and upper part of the buttocks bilaterally | Symmetry | / | ? | 14 |
| 17 | 24 | M | Chest | Symmetry | / | ? | 15 |
| 18 | 18 | M | Face and head | Symmetry | / | ? | 16 |
| 19 | 54 | M | Neck | Symmetry | / | ACV IV 21 days | 17 |
| 20 | 23 | M | Forehead and temporal areas | Symmetry | / | ? | 18 |
| 21 | 55 | M | T4 | Symmetry | / | ACV 800 mg × 5/d 7 days | 10 |
| 22 | 75 | M | Trigeminal nerve dermatome | Symmetry | Prostate carcinoma | ACV | 19 |
| 23 | 70 | M | R: C4, T2 L: L1–2 | Asymmetry | CLL | ACV IV 10 mg/kg/8 h | 20 |
| 24 | 70 | M | R: C4, T4 L: T9–10 | Asymmetry | Diabetic, CKD and MM | ACV 375 mg/d 10 days | 21 |
| 25 | 39 | F | T8 | Symmetry | After thoracoscopic splanchnicectomy | ACV oral 800 mg × 5/d 5 days | 22 |
| 26 | 31 | M | Eyes | Symmetry | AIDS | ACV oral 800 mg × 5/d | 23 |
| 27 | 66 | F | R: C4–5 L: facial and the posterior auricular nerves | Asymmetry | Rheumatism and heart disease | ? | 24 |
| 28 | 63 | M | T11 | Symmetry | ESRD | VCV oral 250 mg/d | 25 |
| 29 | 54 | F | R: T5–7 L: T10 | Asymmetry | MM | FCV | 26 |
| 30 | 52 | F | Face and neck | Symmetry | SLE, TB | ? | 27 |
| 31 | 21 | M | R: T9–10 L: T9 | Asymmetry | UC | Antiviral IV | 28 |
| 32 | 47 | F | L4–5, S1 | Symmetry | Renal transplantation | VCV oral 1 g tid 7 daysVCV oral 1 g/d 6 months | 29 |
| 33 | 27 | M | R: T9 L: T6–8 | Asymmetry | Pharyngotonsillitis | Oseltamivir oral | 30 |
| 34 | 49 | F | T4 | Symmetry | Breast cancer | FCV 700 mg/d 7 days | 31 |
| 35 | 68 | F | R: T8–9 L: C4 | Asymmetry | MM | ACV 750 mg/d 6 days | 32 |
| 36 | 30 | M | T10 | Symmetry | AIDS | ? | 33 |
| 37 | 64 | F | R: L4 L: T10 | Asymmetry | PAAS and diabetes | ACV 10 mg/kg tid | 34 |
| 38 | 67 | F | R: L4–5 L: T7–8 | Asymmetry | Hypertension | FCV 750 mg/d 7 days | 35 |
| 39 | 69 | M | R: T5–7,10,12; L3–4 L: T4–6,12; L3–5 | Asymmetry | ESRD and SCCs | ACV IV 800 mg/d 7 days FCV oral 500 mg/d 14 days | 36 |
| 40 | 91 | F | L2–5 | Symmetry | CKD | Antiviral therapy | 37 |
M male; F female; L left; R right; C cervical; T thoracic; L lumbar; S sacral; IV intravenous; ACV aciclovir; FCV famciclovir; CLL chronic lymphocytic leukaemia; CKD chronic kidney disease; ESRD end-stage renal disease; MM multiple myeloma; AIDS acquired immune deficiency syndrome; SLE systemic lupus erythematosus; TB tuberculosis; UC ulcerative colitis; PAAS polymyositis associated antisynthetase syndrome; SCCs multiple squamous cell carcinomas